Controls
Positive
Crude OR (95% CI) Adjusted OR (95%
CI)
All cases 41 (36.0%) 149 (28.7%) 1.39 (0.88-2.20) 1.54 (0.93-2.55) * Prevalent cases
(n=72)
23 (31.9%) 115 (31.4%) 1.06 (0.60-1.88) 1.14 (0.62-2.10) **
Incident cases (n=35)
15 (42.9%) 29 (20.1%) 2.85 (1.27-6.44) 2.94(1.17-7.42) **
Unscreened cases (n=7)
3 (42.9%) 5 (55.6%) 0.37 (0.030-4.63) Not applicable
Carcinoma in situ (n=54)
17 (31,5%) 68 (26,2%) 1,24 (0,63-2,44) 1,41 (0,65-3,04) **
Invasive Cancer (n=60)
24 (40,0%) 81 (31,3%) 1,49 (0,80-2,78) 1,64 (0,83-3,23) **
* Adjusted for age (five year intervals), area, ever use of oral contraceptives, history of smoking, seropositivity for C. trachomatis and seropositivity for HPV 6, 16 and 18.
** Adjusted for age (50), area, ever use of oral contraceptives and seropositivity for HPV 6, 16 and 18.
REFERENCES
1. Wang PD, Lin RS. Epidemiology of cervical cancer in Taiwan. Gynecol Oncol 1996;62(3):344-52.
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83(1):18-29.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al.
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9.
4. Dillner J, Kallings I, Brihmer C, Sikstrom B, Koskela P, Lehtinen M, et al.
Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996;173(6):1394-8..
5. Silins I, Tedeschi RM, Kallings I, Dillner J. Clustering of seropositivities for sexually transmitted infections. Sex Transm Dis 2002;29(4):207-11..
6. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88(1):63-73..
7. Naucler P, Da Costa FM, Ljungberg O, Bugalho A, Dillner J. Human papillomavirus genotypes in cervical cancers in Mozambique. J Gen Virol 2004;85(Pt 8):2189-90.
8. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, et al.
Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995;171(4):1026-30.
9. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al.
Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169(2):235-40.
10. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of
cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338(7):423-8.
11. Olsen AO, Dillner J, Gjoen K, Magnus P. Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med
1997;73(2):131-5.
12. af Geijersstam V, Kibur M, Wang Z, Koskela P, Pukkala E, Schiller J, et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis
1998;177(6):1710-4.
13. Shah KV, Viscidi RP, Alberg AJ, Helzlsouer KJ, Comstock GW. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 1997;6(4):233-7.
14. Wang Z, Konya J, Avall-Lundkvist E, Sapp M, Dillner J, Dillner L. Human
papillomavirus antibody responses among patients with incident cervical carcinoma. J Med Virol 1997;52(4):436-40.
15. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, et al.
Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. Bmj 1996;312(7030):537-9.
16. Dillner J, Lehtinen M, Bjorge T, Luostarinen T, Youngman L, Jellum E, et al.
Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for
invasive cervical cancer. J Natl Cancer Inst 1997;89(17):1293-9.
17. Sigurgeirsson B, Lindelof B, Eklund G. Condylomata acuminata and risk of cancer:
an epidemiological study. Bmj 1991;303(6798):341-4.
18. Luostarinen T, Lehtinen M, Bjorge T, Abeler V, Hakama M, Hallmans G, et al. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer 2004;40(7):1058-65.
19. Silins I, Wang Z, Avall-Lundqvist E, Frankendal B, Vikmanis U, Sapp M, et al.
Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol 1999;80 (Pt 11):2931-6.
20. Luostarinen T, af Geijersstam V, Bjorge T, Eklund C, Hakama M, Hakulinen T, et al.
No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 1999;80(6):818-22.
21. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al.
Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92(6):464-74.
22. Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. Jama 2001;285(1):47-51.
23. Koskela P, Anttila T, Bjorge T, Brunsvig A, Dillner J, Hakama M, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer
2000;85(1):35-9.
24. Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric
case-control study. Int J Cancer 2004;111(3):431-9.
25. Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction.
Hum Reprod Update 1999;5(5):433-47.
26. Silins I, Ryd W, Strand A, Wadell G, Tornberg S, Hansson BG, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer
2005;116(1):110-5.
27. Zenilman JM. Chlamydia and cervical cancer: a real association? Jama 2001;285(1):81-3.
28. Liaw KL, Hsing AW, Chen CJ, Schiffman MH, Zhang TY, Hsieh CY, et al. Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int J Cancer
1995;62(5):565-71.
29. Sun CA, Liu JF, Wu DM, Nieh S, Yu CP, Chu TY. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet
2002;76(1):41-7.
30. Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1992;84(6):394-8.
31. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993;67(12):6929-36.
32. Kjellberg L, Wang Z, Wiklund F, Edlund K, Angstrom T, Lenner P, et al. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a
population-based case-control study. J Gen Virol 1999;80 (Pt 2):391-8.
33. Dillner J, Wiklund F, Lenner P, Eklund C, Frederiksson-Shanazarian V, Schiller JT, et al. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer 1995;60(3):377-82.
34. Andersson-Ellstrom A, Dillner J, Hagmar B, Schiller J, Sapp M, Forssman L, et al.
Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 1996;23(3):234-8.
35. Grabowska K, Wang X, Jacobsson A, Dillner J. Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. J Immunol Methods 2002;271(1-2):1-15.
36. Silins I, Wang X, Tadesse A, Jansen KU, Schiller JT, Avall-Lundqvist E, et al. A population-based study of cervical carcinoma and HPV infection in Latvia. Gynecol Oncol 2004;93(2):484-92.
37. Wang SP, Grayston JT. Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. Am J Ophthalmol 1970;70(3):367-74.
38. Rothman KJ, Greenland S. Modern epidemiology, ed. 2nd. Philadelphia:
Lippincott-Raven, 1998.
39. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction.
Epidemiology 1992;3(5):452-6.
40. Combita AL, Bravo MM, Touze A, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer 2002;97(6):796-803.
41. Matsumoto K, Yoshikawa H, Yasugi T, Nakagawa S, Kawana K, Takeoka A, et al.
IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan. J Med Virol 2003;69(3):441-6.
42. Wang PD, Lin RS. Risk factors for cervical intraepithelial neoplasia in Taiwan.
Gynecol Oncol 1996;62(1):10-8.
43. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87(11):796-802.
44. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al.
Epidemiologic classification of human papillomavirus types associated with cervical cancer.
N Engl J Med 2003;348(6):518-27.
45. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al.
Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132(10):810-9.